| 18.8 18.8 (1.68%) | 04-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 25.69  |
1-year : | 30.01 |
| Resists | First : | 22 |
Second : | 25.69 |
| Pivot price | 17.31 |
|||
| Supports | First : | 17.96 |
Second : | 15.47 |
| MAs | MA(5) : | 17.56 |
MA(20) : | 17.16 |
| MA(100) : | 17.07 |
MA(250) : | 9.87 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 75.9 |
D(3) : | 59.2 |
| RSI | RSI(14): 55.2 |
|||
| 52-week | High : | 24 | Low : | 3.67 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ BIOA ] has closed below upper band by 5.0%. Bollinger Bands are 34.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 18.96 - 19.02 | 19.02 - 19.08 |
| Low: | 17.53 - 17.59 | 17.59 - 17.67 |
| Close: | 18.68 - 18.78 | 18.78 - 18.9 |
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Wed, 15 Apr 2026
BioAge Labs - Oral NLRP3 Inhibitor Could Establish PoC In CV This Year (NASDAQ:BIOA) - Seeking Alpha
Mon, 13 Apr 2026
BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Mon, 13 Apr 2026
BioAge CEO's April 16 fireside chat will stream live online - Stock Titan
Fri, 10 Apr 2026
BioAge Labs (NASDAQ:BIOA) Shares Down 6% - Here's What Happened - MarketBeat
Thu, 09 Apr 2026
BioAge Labs, Inc. (NASDAQ:BIOA) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Tue, 07 Apr 2026
Should I buy BioAge Labs, Inc. (BIOA) - Zacks Investment Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 44 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 2.4 (%) |
| Held by Institutions | 61.2 (%) |
| Shares Short | 1,560 (K) |
| Shares Short P.Month | 1,280 (K) |
| EPS | -2.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.28 |
| Profit Margin | 0 % |
| Operating Margin | -923.5 % |
| Return on Assets (ttm) | -17.8 % |
| Return on Equity (ttm) | -27.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.47 |
| Sales Per Share | 0.2 |
| EBITDA (p.s.) | -2.09 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -82 (M) |
| Levered Free Cash Flow | -55 (M) |
| PE Ratio | -8.4 |
| PEG Ratio | 0 |
| Price to Book value | 2.58 |
| Price to Sales | 92.8 |
| Price to Cash Flow | -10.23 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|